Fate Therapeutics, Inc. (FATE)
2.09
-0.08
(-3.69%)
USD |
NASDAQ |
Oct 30, 16:00
2.09
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Cash from Investing (Quarterly) : 14.56M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 14.56M |
| March 31, 2026 | 23.59M |
| December 31, 2025 | 27.63M |
| September 30, 2025 | 21.27M |
| June 30, 2025 | 19.59M |
| March 31, 2025 | 42.67M |
| December 31, 2024 | 22.82M |
| September 30, 2024 | 25.46M |
| June 30, 2024 | -53.37M |
| March 31, 2024 | 17.31M |
| December 31, 2023 | 45.35M |
| September 30, 2023 | 24.80M |
| June 30, 2023 | 33.17M |
| March 31, 2023 | 9.34M |
| December 31, 2022 | 53.11M |
| September 30, 2022 | 80.38M |
| June 30, 2022 | 40.29M |
| March 31, 2022 | -7.026M |
| December 31, 2021 | 71.28M |
| September 30, 2021 | 77.96M |
| June 30, 2021 | -1.372M |
| March 31, 2021 | -471.89M |
| December 31, 2020 | -166.03M |
| September 30, 2020 | -54.14M |
| June 30, 2020 | 35.32M |
| Date | Value |
|---|---|
| March 31, 2020 | 23.77M |
| December 31, 2019 | -110.52M |
| September 30, 2019 | 36.29M |
| June 30, 2019 | -91.98M |
| March 31, 2019 | 8.754M |
| December 31, 2018 | 16.38M |
| September 30, 2018 | 13.28M |
| June 30, 2018 | 13.72M |
| March 31, 2018 | -43.84M |
| December 31, 2017 | 13.20M |
| September 30, 2017 | 13.64M |
| June 30, 2017 | 1.339M |
| March 31, 2017 | -38.38M |
| December 31, 2016 | 5.978M |
| September 30, 2016 | 0.458M |
| June 30, 2016 | 5.794M |
| March 31, 2016 | -16.34M |
| December 31, 2015 | -0.178M |
| September 30, 2015 | -0.655M |
| June 30, 2015 | -0.213M |
| March 31, 2015 | -0.452M |
| December 31, 2014 | -0.271M |
| September 30, 2014 | -0.187M |
| June 30, 2014 | -0.026M |
| March 31, 2014 | -0.398M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AVITA Medical, Inc. | 3.947M |
| Agenus, Inc. | 0.267M |
| Amgen, Inc. | -569.00M |
| Anika Therapeutics, Inc. | -1.28M |
| BioCryst Pharmaceuticals, Inc. | -110.15M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -23.43M |
| Cash from Financing (Quarterly) | 1.736M |
| Free Cash Flow | -105.66M |
| Free Cash Flow Per Share (Quarterly) | -0.1953 |
| Free Cash Flow to Equity (Quarterly) | -22.40M |
| Free Cash Flow to Firm (Quarterly) | -23.51M |
| Free Cash Flow Yield | -42.25% |